Ukraine can join India, Israel, and Thailand and become another major platform for the rapidly growing industry of clinical trials of new drugs, James Peyer, managing partner of the U.S. biotechnology company Apollo Ventures, has said. “Clinical trials can be carried out (in Ukraine) with the same level of professionalism, with the same level of effectiveness as in the United States and Europe but without their high costs,” he said at the Ukraine House Davos health panel.
As reported earlier, bill No. 4074 on ensuring public access to the results of preclinical study and clinical trials of medicines was passed into law by the Ukrainian parliament in September 2018.
At present, about 200 clinical drug trials are underway in Ukraine. At the same time, in the past two years, the trend toward a decrease in the number of clinical trials has subsided.
Trade turnover between Ukraine and India in January-October 2018 amounted to $2.3 billion, of which $1.5 billion was the cost of sunflower oil, First Deputy Prime Minister, Minister of Economic Development and Trade Stepan Kubiv has said. “India ranks first in terms of exports of Ukrainian goods to the countries of the Asia-Pacific region and is the fifth largest buyer of Ukrainian products among countries in the world,” he wrote on Facebook.
The Ministry of Economic Development and Trade said on Twitter the Ukrainian delegation headed by Kubiv on January 11-13 is on a working visit to India to participate in the 25th international summit “New India: Rising to Global Occasions.”
India could expand a portfolio of generics exported to Ukraine thanks to medications that lost patent protection of innovative drugs, which will become available before 2020, President of the Indian Pharmaceutical Manufacturers’ Association (IPMA) Dr. Ramanan Unni Parambath Menon has told Interfax-Ukraine. “Exports of Indian pharmaceutical products will grow, and the portfolio of generic products that can be supplied to Ukraine will expand, since by 2020 branded drugs worth about $55 billion will lose patent protection,” he said on the sidelines of the annual business seminar “India – Global force in pharmaceutics – Reliable partner for Ukraine” held late November in Kyiv.
He said that at present, retail and hospital sales of Indian medicines account for more than UAH 2.633 billion per year, including UAH 334.3 million in the hospital segment. The share of branded generic production of Indian pharmaceutical companies is 59.4% of this segment. According to Dr. Menon, “generic products are market drivers.” “The share of generic drugs is growing in monetary terms and in kind. Products of Indian companies are more branded generics,” he said.
Currently, the top 10 Indian pharmaceutical companies on the Ukrainian market include five IPMA member companies – Dr. Reddys, Abryl Formulations, Organosyn Life Sciences, SUN Pharma, Macleods Pharmaceuticals; and two IPMA member companies are in the top 20 – Aurobindo Pharma and Hetero Labs.
In total, 365 Indian brands are currently represented in the Ukrainian pharmaceutical market.
The IPMA predicts that by the end of 2018, sales of Indian medicines in Ukraine will grow by 22.7% in hryvnias or 19.9% in U.S. dollars compared with 2017. At the same time, sales of Indian drugs in kind will increase by 2.5%.
The growth in sales of Indian pharmaceutical products in 2019 in monetary terms could be 18.1% in hryvnias or 9.5% in U.S. dollars, while maintaining the total supply volumes.
The Embassy of India in Kyiv, in association with Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) and Indian Pharmaceuticals Manufacturers Association (IPMA), Ukraine is organizing the annual business seminar on pharmaceutical and herbal sectors “India- a Global Power in Pharmaceutical Sector: a Reliable Partner for Ukraine” on 30th November, 2018 in Kyiv to promote and display the potential of India in these sectors.
For more information, please send a request to the e-mail email@example.com.
Accreditation for media representatives is obligatory under the following link: goo.gl/7cGuVS
The Embassy of India in Kyiv in cooperation with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and the Indian Pharmaceutical Manufacturers Association (IPMA) will hold an annual business seminar in Ukraine to promote and demonstrate the potential of India in the pharmaceutical manufacturing sectors, Indian Ambassador to Ukraine Partha Satpathy has stated at a press conference at Interfax-Ukraine. “Pharmexcil is the Pharmaceuticals Export Promotion Council of India. The main task of this organization is to unite all important pharmaceutical manufacturers in India. The council cooperates with the government, represents the interests of manufacturers in exports, in particular brings pharmaceutical products in compliance with the requirements of the WHO and the importing country,” the ambassador said.
President of the Indian Pharmaceutical Manufacturers Association (IPMA) Dr. Menon, in turn, said that Pharmexcil plans to present several projects in Ukraine.
“Pharmexcil wants to find partners in Ukraine in the field of Ayurveda, clinical trials and create a joint venture for production of medicines,” he said.
The Indian ambassador noted that India is the third largest exporter of pharmaceutical products to Ukraine following Germany and France in terms of value, while Indian pharmaceutical companies supply high-quality products at a very good and competitive price.
State-owned enterprise (SOE) Spetstechnoexport is boosting defense cooperation with India and opening its second representative office on the largest defense market of the South Asian region. The press service of the company reported on Tuesday that the representative office of Spetstechnoexport opened in October in Nashik, India, will provide operational and effective cooperation with Indian partners, including the implementation of the new arrangements in the defense cooperation sphere signed by Ukraine in 2018 with Hindustan Aeronautics Limited (HAL) and Bharat Electronics Limited (BEL).
According to the report, the new arrangements with HAL foresee expansion of defense cooperation in the aviation cluster, in particular, the supply of defense systems for Indian helicopters, joint research and the developments, establishment of production of specific aviation systems in India.
Spetstechnoexport engages Ukrainian defense enterprises in cooperation with the HAL, in particular the Lviv State Aircraft Repair Plant, the Odesa Aviation Plant, SOE Institute for scientific research Storm, SOE Kharkiv Machine-Building Plant FED, the Kharkiv Aggregate Design Bureau, SOE Novator, Radionix LLC and others.
The possibility of closer communication with foreign partners allows increasing the volume of cooperation, the company said. This year, Spetstechnoexport has almost tripled the volume of supplies of defense products to the needs of the Hindustan Aeronautics Limited aircraft division compared to the level of 2016.
Spetstechnoexport has an opportunity to take part in tenders for joint modernization of radars P-18 and ST-68, as well as air defense systems, such as ZSU-23-4 Shilka, P-125 Pechora and others under new arrangements with BEL.
The press service said that during the DefExpo 2018 international defense exhibition in India, Spetstechnoexport signed new contracts in the aviation sector with the total cost of about $20 million.